I think ClosureFAST reprocessing is going to have a bigger impact in Q1 than most think, but more importantly, it's going to have a bigger impact on Q2 guidance.
If approximately 4% of doctors signed up in less than 2 weeks, I'd guess that about 20-25% of doctors will have signed up by the end of the quarter (this will save the average doctor about 10k per year).
Based on that, I think Vascular will get between $300-$400k of revenue and it will add about .01 per share in earnings. I would expect eps to be .12 on revenue of $22.8 million, both beating guidance. Q2 revenue should be $1.5M+ and add .03 to eps. They'll definitely do $5M in this business in 2012.